Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 2/20 | 0.54 |
| ▸ | TUBB | P07437 | 2/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.54 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.54 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.54 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.54 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.54 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.54 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.54 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14674682 | 0.87 | ESR1 (0.51) | L3MBTL1HTR7ESR1ESR2ALDH1A1 | |
| SCHEMBL2800404 | 0.84 | ESR1 (0.63) | TSHRL3MBTL1HTR7ESR1ESR2 | |
| SCHEMBL19423102 | 0.83 | TUBB4A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL20695860 | 0.83 | TUBB4A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29975007 | 0.80 | L3MBTL1 (0.56) | L3MBTL1ESR1ESR2ALDH1A1KDM4E | |
| SCHEMBL1997854 | 0.80 | L3MBTL1 (0.56) | L3MBTL1ESR1ESR2ALDH1A1KDM4E | |
| SCHEMBL14412033 | 0.78 | KMT2A (0.62) | L3MBTL1HTR7ESR1ESR2ALDH1A1 | |
| SCHEMBL15841548 | 0.77 | GFER (0.60) | TSHRL3MBTL1ESR1ESR2ALDH1A1 | |
| SCHEMBL15841547 | 0.77 | GFER (0.60) | TSHRL3MBTL1ESR1ESR2ALDH1A1 | |
| SCHEMBL1997707 | 0.77 | HTR7 (0.42) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309734-A1 | COMBRETASTATIN DERIVATIVES AND USES THEREFOR | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2012-12-06 | — | — | US | disclosed |
| EP-2513051-A1 | COMBRETASTATIN DERIVATIVES AND USES THEREFOR | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin (IE) | 2012-10-24 | — | — | EP | disclosed |
| EP-2338877-A1 | Combretastatin Derivatives and Uses Therefor | The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin (IE) | 2011-06-29 | — | — | EP | disclosed |
| WO-2011073211-A1 | COMBRETASTATIN DERIVATIVES AND USES THEREFOR | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309734-A1 | COMBRETASTATIN DERIVATIVES AND USES THEREFOR | CASP4, CA4, ACSL4 | TUBB4A 157/4885TUBB 699/4885TUBA3C 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.